{
    "clinical_study": {
        "@rank": "99331", 
        "acronym": "PTH", 
        "arm_group": [
            {
                "arm_group_label": "Ganciclovir", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with a positive CMV PCR"
            }, 
            {
                "arm_group_label": "Ganciclovir placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients with a positive CMV PCR"
            }, 
            {
                "arm_group_label": "Aciclovir", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with a PCR positive for HSV"
            }, 
            {
                "arm_group_label": "Aciclovir placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients with a positive PCR for HSV"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to show that a preemptive treatment by ganciclovir (for positive\n      CMV viremia) or aciclovir (for positive HSV oro-pharyngeal PCR) is able to increase the\n      number of ventilator-free days at Day 60."
        }, 
        "brief_title": "PTH - Preemptive Treatment for Herpesviridae", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Viral Pneumonia", 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia", 
                "Pneumonia, Viral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  mechanical ventilation > 96 hrs and expected duration of mechanical ventilation of at\n             least 2 days\n\n          -  positive blood CMV PCR (500 IU/ml) OR positive oropharyngeal HSV PCR\n\n          -  age > 18 years\n\n          -  informed consent\n\n          -  negative pregnancy test\n\n        Exclusion Criteria:\n\n          -  < 18 years\n\n          -  Receiving ganciclovir or aciclovir or another antiviral agent active against HSV/CMV\n\n          -  Had received antiviral agent active against HSV/CMV during the previous month\n\n          -  Hypersensitivity to aciclovir/ganciclovir\n\n          -  Pregnancy\n\n          -  Breast feeding\n\n          -  Bone marrow failure\n\n          -  Solid organ recipients\n\n          -  Bone marrow recipients\n\n          -  HIV positive patients\n\n          -  Receiving immunosuppressive agents\n\n          -  SAPS II > 75\n\n          -  Withdrawing/withholding\n\n          -  Neutropenia (< 500 mm3)\n\n          -  Thrombocytopenia (< 25 G/L)\n\n          -  ICU readmission"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152358", 
            "org_study_id": "20126003312-30", 
            "secondary_id": "2012-003312-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aciclovir", 
                "description": "Intravenous 15 mg/kg/d during 14 days", 
                "intervention_name": "Aciclovir", 
                "intervention_type": "Drug", 
                "other_name": "aciclovir"
            }, 
            {
                "arm_group_label": "Ganciclovir", 
                "description": "intravenous 10 mg/kg/d for 14 days", 
                "intervention_name": "Ganciclovir", 
                "intervention_type": "Drug", 
                "other_name": "ganciclovir"
            }, 
            {
                "arm_group_label": [
                    "Ganciclovir placebo", 
                    "Aciclovir placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acyclovir", 
                "Ganciclovir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cytomegalovirus", 
            "Herpes simplex virus", 
            "ICU", 
            "mechanical ventilation", 
            "mortality", 
            "ventilator-free days", 
            "PCR"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "last_name": "Laurent Papazian, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Marseille", 
                    "country": "France", 
                    "zip": "13015"
                }, 
                "name": "Assistance Publique - H\u00f4pitaux de Marseille"
            }, 
            "investigator": {
                "last_name": "Laurent Papazian, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Efficacy of a Preemptive Treatment by Ganciclovir or by Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting a Viral Replication (CMV and/or HSV) - Prospective, Randomized, Double-blinded Multicenter Trial", 
        "overall_contact": {
            "email": "laurent.papazian@ap-hm.fr", 
            "last_name": "Laurent Papazian, MD, PhD", 
            "phone": "+33491965836"
        }, 
        "overall_contact_backup": {
            "email": "jean-charles.reynier@ap-hm.fr", 
            "last_name": "Jean-Charles Reynier, MD", 
            "phone": "+33491382747"
        }, 
        "overall_official": {
            "affiliation": "APHM - AMU", 
            "last_name": "Laurent Papazian, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ventilator-free days at Day 60", 
            "safety_issue": "No", 
            "time_frame": "60 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Day 60 mortality", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "ICU mortality", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Hospital mortality", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Duration of mechanical ventilation in survivors", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Duration of ICU stay", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Duration of hospital stay", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Incidence of ventilator-associated pneumonia", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Incidence of bacteremia", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "SOFA score", 
                "safety_issue": "No", 
                "time_frame": "days 3, 5, 7, 14, 21 and 28"
            }, 
            {
                "measure": "Acute renal failure related to aciclovir or its placebo", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Leucopenia related to ganciclovir or its placebo", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Time to oropharyngeal negativation of HSV PCR", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Time to blood negativation of CMV PCR", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Incidence of herpetic bronchopneumonia", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Incidence of active CMV infection", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }
        ], 
        "source": "Assistance Publique Hopitaux De Marseille", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique Hopitaux De Marseille", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}